Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. More Details
High growth potential with mediocre balance sheet.
Share Price & News
How has Coherus BioSciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CHRS's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CHRS underperformed the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: CHRS underperformed the US Market which returned 49.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Coherus BioSciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
10 hours ago | Simply Wall StDid Coherus BioSciences, Inc. (NASDAQ:CHRS) Insiders Sell Shares?
3 weeks ago | Simply Wall StA Closer Look At Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Impressive ROE
1 month ago | Simply Wall StWith EPS Growth And More, Coherus BioSciences (NASDAQ:CHRS) Is Interesting
Is Coherus BioSciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CHRS ($14.32) is trading below our estimate of fair value ($93.92)
Significantly Below Fair Value: CHRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CHRS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CHRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHRS is overvalued based on its PB Ratio (8.2x) compared to the US Biotechs industry average (3.5x).
How is Coherus BioSciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CHRS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CHRS's is expected to become profitable in the next 3 years.
Revenue vs Market: CHRS's revenue (22.9% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: CHRS's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CHRS is forecast to be unprofitable in 3 years.
How has Coherus BioSciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHRS is currently unprofitable.
Growing Profit Margin: CHRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CHRS is unprofitable, but has reduced losses over the past 5 years at a rate of 43.8% per year.
Accelerating Growth: Unable to compare CHRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: CHRS has a negative Return on Equity (-59.74%), as it is currently unprofitable.
How is Coherus BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: CHRS's short term assets ($617.3M) exceed its short term liabilities ($257.6M).
Long Term Liabilities: CHRS's short term assets ($617.3M) exceed its long term liabilities ($308.0M).
Debt to Equity History and Analysis
Debt Level: CHRS's debt to equity ratio (317.2%) is considered high.
Reducing Debt: CHRS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if CHRS has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CHRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Coherus BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Denny Lanfear (65 yo)
Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...
CEO Compensation Analysis
Compensation vs Market: Denny's total compensation ($USD7.28M) is above average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Denny's compensation has increased whilst the company is unprofitable.
Experienced Management: CHRS's management team is considered experienced (2.5 years average tenure).
Experienced Board: CHRS's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CHRS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.8%.
Coherus BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Coherus BioSciences, Inc.
- Ticker: CHRS
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.085b
- Shares outstanding: 75.75m
- Website: https://www.coherus.com
Number of Employees
- Coherus BioSciences, Inc.
- 333 Twin Dolphin Drive
- Suite 600
- Redwood City
- United States
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-ac...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 11:44|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.